Reply from authors re: Stacy Loeb. Use of baseline prostate-specific antigen measurements to personalize prostate cancer screening. Eur Urol 2012;61:875-6

European Urology

Volumn 61, Issue 5, 2012, Pages 876-877

  Ørsted, David D ^a,b   Nordestgaard, Børge G ^a,b,c   Jensen, Gorm B ^c   Schnohr, Peter ^c   Bojesen, Stig E ^a,b,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; DISEASE ASSOCIATION; HEALTH CARE SYSTEM; HUMAN; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

EID: 84859424444     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.12.022     Document Type: Editorial

References (10)

1. S. Loeb Use of baseline prostate-specific antigen measurements to personalize prostate cancer screening Eur Urol 61 2012 875 876
2. D.D. Ørsted, B.G. Nordestgaard, G.B. Jensen, P. Schnohr, and S.E. Bojesen Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population Eur Urol 61 2012 865 874
3. X. Zhu, P.C. Albertsen, and G.L. Andriole Risk-based prostate cancer screening Eur Urol. 61 2012 652 661
4. Carroll P, Albertsen PC, Greene K, et al. Prostate-specific antigen best practice statement: 2009 update. American Urological Association Web site. www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/ main-reports/psa09.pdf.
5. A.J. Vickers, A.M. Cronin, and T. Bjork Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study BMJ 341 2010 4521 4529
6. M.J. Roobol, D.W. Roobol, and F.H. Schroder Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/ml or less in a population-based screening setting? (ERSPC, section Rotterdam) Urology 65 2005 343 346 (Pubitemid 40248025)
7. R. Chou, J.M. Croswell, and T. Dana Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 155 2011 762 771
8. P.C. Albertsen, D.F. Moore, and W. Shih Impact of comorbidity on survival among men with localized prostate cancer J Clin Oncol 29 2011 1335 1341
9. D.D. Ørsted, S.E. Bojesen, S.F. Nielsen, and B.G. Nordestgaard Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3 009 258 men Eur Urol 60 2011 691 698
10. D. Ulmert, A.M. Serio, and M.F. O'Brien Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population J Clin Oncol 26 2008 835 841 (Pubitemid 351398073)